Identifying the profile of optimal candidates for antipsychotic depot therapy

Heres, Stephan; Hamann, Johannes; Mendel, Rosmarie; Wickelmaier, Florian; Pajonk, Frank-Gerald B.; Leucht, Stefan; Kissling, Werner

doi:10.1016/j.pnpbp.2008.09.025

Cited by 35 publications

(51 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, although LAIs are widely recognized to be adherence-enhancing and strongly preventive of relapse, a great number of psychiatrists seemed to avoid prescribing depot antipsychotics especially for patients with FES [22]. In fact, concerning FES, some of the common reasons against early usage of LAIs are the long-established association of depot treatment as a coercive and stigmatizing therapy, the recommendation of guidelines to use first oral antipsychotics, the belief that a good therapeutic relationship may be a pro-adherence factor, the relative lack of long-term studies and the tolerability profile of LAIs [23]. Psychiatrists frequently imagine that patients with FES would not accept depot antipsychotics and that depots are generally eligible for chronic patients [24].…”

Section: Editorialmentioning

confidence: 99%

Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia:“Lights”and“Shadows”

Berardis¹

2016

J Neuropsychopharmacol Mental Health

View full text Add to dashboard Cite

Section: Editorialmentioning

confidence: 99%

Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia:“Lights”and“Shadows”

Berardis¹

2016

J Neuropsychopharmacol Mental Health

View full text Add to dashboard Cite

“…A cluster analysis published in 2008 aimed at identifying the profile of optimal candidates for antipsychotic depot therapy [Heres et al 2008]. A group of 201 psychiatrists had to rate on an 11-point scale to what extent 14 different attributes of patients influenced their qualification for antipsychotic depot treatment (0 = not qualifying for depot treatment to 10 = highly qualifying for depot treatment).…”

Section: Staff Attitudesmentioning

confidence: 99%

Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

Kirschner

Theodoridou

Fusar‐Poli

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Objectives: The acceptance and use of long-acting depot antipsychotics has been shown to be influenced by the attitudes of patients and clinicians. Depot treatment rates are low across countries and especially patients with first-episode psychosis are rarely treated with depot medication. The aim of this article was to review the literature on patients' and clinicians' attitudes towards long-acting depot antipsychotics in subjects with first-episode psychosis. Methods: A systematic search of Medline, Embase, PsycINF and Google Scholar was conducted. Studies were included if they reported original data describing patients' and clinicians' attitudes towards long-acting depot antipsychotic in subjects with first-episode psychosis. Results: Six studies out of a total of 503 articles met the inclusion criteria. Four studies conveyed a negative and two a positive opinion of clinicians toward depot medication. No systematic study directly addressed the attitude of patients with first-episode psychosis. Psychiatrists frequently presume that patients with first-episode psychosis would not accept depot medication and that depots are mostly eligible for chronic patients. Conclusions: Full information of all patients especially those with first episode psychosis in a therapeutic relationship that includes shared decision-making processes could reduce the negative image and stigmatization attached to depots.

show abstract

“…After acceptation, each psychiatrist was interviewed individually for 40 minutes using a single questionnaire devised by adapting questionnaires used in two separate studies conducted in different samples of German psychiatrists (Heres et al, 2006(Heres et al, , 2008.…”

Section: Procedures and Instrumentsmentioning

confidence: 99%

1151 – Clinicians’ attitudes toward the use of long-acting injectable antipsychotics

Samalin

Charpeaud

Heres³

et al. 2013

European Psychiatry

View full text Add to dashboard Cite

Depot formulations are not widely used in everyday practice. This study aimed to assess psychiatrists' attitudes toward the use of long-acting injectable (LAI) antipsychotics in schizophrenia. We interviewed 113 French psychiatrists about the factors that influenced their prescription of LAI antipsychotics. Multidimensional and cluster analyses were used to detect correlations. The most important factor against the use of LAI antipsychotics is a sufficient estimated compliance with the oral formulation. For first-generation LAI, the main factor is the risk for extrapyramidal symptoms; and for secondgeneration LAI, it is the unavailability of the equivalent oral formulation. Four factors incite the psychiatrists to prescribe LAI. Two different clusters of patients can also be identified. Most factors influencing the clinicians' attitudes toward the use of LAI antipsychotics are shared in many countries. Conversely, some attitudes related to organizational aspects, particularly the relevance of health care costs, may vary from one country to another.Key Words: Antipsychotics, long-acting injectable, attitudes, schizophrenia (J Nerv Ment Dis 2013;201: 553Y559) A ccording to systematic reviews, between 40% and 60% of patients with schizophrenia are known to be partially or totally noncompliant to oral antipsychotic medication (Dolder et al., 2002;Valenstein et al., 2004). Poor adherence is associated with higher risk for relapse of schizophrenia and increased health care costs (Patel et al., 2008).However, depot formulations are not widely used in routine practice, with a prescription rate of generally lower than 30% in different countries (Barnes et al., 2009; Patel and David, 2011). However, the use of long-acting injectable (LAI) formulations varies between countries. The prescription rates are higher in France (23.5%;Fourrier et al., 2000) and in the United Kingdom (29%; Barnes et al., 2009) compared with other European countries and with Canada (6.3%; Williams et al., 2006) or the United States (17.6%; West et al., 2008).This discrepancy between countries can be considered to derive from the health care system and from the different attitudes displayed by psychiatrists.Perceived coercion or presumed risks for lower tolerance of depot forms have been identified as factors responsible for this low use (Heres et al., 2006; Patel and David, 2011). More generally, negative attitudes from practitioners toward these forms have been shown to account for part of the low prescription rates of depot antipsychotics (Hamann et al., 2010;Heres et al., 2006Heres et al., , 2008Heres et al., , 2011.The main goal of our study was to assess the attitudes of psychiatrists toward LAI antipsychotics in patients with schizophrenia to understand the reasons for using or not assigning depot treatment.We studied these attitudes in a sample of psychiatrists working in France using the same questionnaire that was used in a population of German psychiatrists (Heres et al., 2006(Heres et al., , 2008. Our results will be discus...

show abstract

Identifying the profile of optimal candidates for antipsychotic depot therapy

Cited by 35 publications

References 29 publications

Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia:“Lights”and“Shadows”

Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia:“Lights”and“Shadows”

Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

1151 – Clinicians’ attitudes toward the use of long-acting injectable antipsychotics

Contact Info

Product

Resources

About